Clinical Trial Details
— Status: Completed
Administrative data
| NCT number |
NCT04160676 |
| Other study ID # |
33375/09/19 |
| Secondary ID |
|
| Status |
Completed |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
December 1, 2019 |
| Est. completion date |
July 26, 2021 |
Study information
| Verified date |
July 2021 |
| Source |
Tanta University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
In this study , we suggest that the use of combination of Hydrocortisone, Ascorbic Acid, and
Thiamine in patient with sepsis may decrease mortality rate and improve the outcome.
This study will be carried out at SICU of Tanta University hospitals on Patients aged from 18
to 65 years old who will be presented with sepsis that diagnosed according to the surviving
sepsis campaign 2016.
Patients who will meet the previous criteria will be enrolled in the study. The patients will
be randomized allocated into two groups by the aid of computer generated software of
randomization introduced into sealed closed envelops.
All patients will receive the conventional therapy according to the surviving sepsis campaign
2016 and The Surviving Sepsis Campaign Bundle 2018 Update.
The patients will be allocated randomly into one of the following two groups;-. Group I The
patients in this group will be managed only according to the surviving sepsis campaign 2016
and the surviving sepsis campaign bundle 2018 update.
The patients will receive 50 ml normal saline I.V within 30 mins / 6 h, 10 ml normal saline
I.V / 6 h, 5 ml normal saline I.V / 12 h.
Group II The patients will receive the conventional therapy of sepsis and combined therapy of
hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml
normal saline IV / 6 h, ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5
gm diluted in 50 ml normal saline IV within 30 min /6 h , and thiamine (Vitamin
B1-injektopas®, Ampoule, Germany, 100 mg / 2 ml) 200 mg diluted in 10 ml normal saline IV /12
h The outcome of the patients, the incidence of organ dysfunction will be assessed.
Description:
This prospective randomized controlled double-blinded study will be carried out at surgical
intensive care units (SICU) in Tanta University Hospitals for a period of 12 months that may
be extended after approval from institutional ethical committee.
An informed written consent will be obtained from the patients or patients' relatives.
They will receive an explanation of the purpose of the study and every patient will have a
secret code number.
Research results will be only used for scientific purpose. Any unexpected risk/s appearing
during the course of research will be clarified to the participants and to the ethical
committee on time, however, the patients that will be enrolled in this study have no expected
additional risk as we use Hydrocortisone, Ascorbic acid and Thiamin that have minimal side
effects.
*Inclusion criteria: Patients aged from 18 to 65 years old who will be presented with sepsis
that diagnosed according to the surviving sepsis campaign 2016(21) and The Surviving Sepsis
Campaign Bundle 2018 Update.
*Exclusion Criteria:
- Participant or participants' relatives refusal to continue the study.
- Known or suspected allergy to the studied medications.
- Contraindications to the use of vitamin C as renal stones, Alzheimer's disease and
Schizophrenia.
- Pre-existing organ failure or dysfunction not related to the presenting sepsis
condition.
- Pregnancy.
Patients who will meet the previous criteria will be enrolled in the study. The patients will
be randomized allocated into two groups by the aid of computer generated software of
randomization introduced into sealed closed envelops.
All patients will receive the conventional therapy according to the surviving sepsis campaign
2016 and The Surviving Sepsis Campaign Bundle 2018 Update.
An intensivist who has no further role in this research work will help in the preparation of
the used medications in syringes that will contain medications in group two and normal saline
in group one.
(placebo) -I Group The patients in this group will be managed only according to the surviving
sepsis campaign 2016 and the surviving sepsis campaign bundle 2018 update.
The patients will receive 50 ml normal saline I.V within 30 mins / 6 h, 10 ml normal saline
I.V / 6 h, 5 ml normal saline I.V / 12 h.
Group II The patients will receive the conventional therapy of sepsis and combined therapy of
hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml
normal saline IV / 6 h, ascorbic acid (VITAMIN C-®, Amp, ROTEXMEDICA, Germany, 500mg/5ml) 1.5
gm diluted in 50 ml normal saline IV within 30 min /6 h , and thiamine (Vitamin
B1-injektopas®, Ampoule, Germany, 100 mg / 2 ml) 200 mg diluted in 10 ml normal saline IV /12
h This combined therapy will be given for 4 days or to the time of discharge if the admission
period is less than 4 days.
*Measurements
All data will be collected by intensivists who will be blinded about the study groups. All
the patients will be subjected to the following:
1. Demographic data (age, gender, weight, cause of sepsis).
2. 28th day mortality (If the patient will be discharged, data will be collected by phone
calls)
3. Sofa score will be recorded daily and compared during the period of the studied drugs
administration.
4. Incidence of organ dysfunction during the period of ICU stay.
5. Mean arterial blood pressure will be recorded every 8 hrs and compared during the period
of the studied drugs adminstration.
6. Cardiac index will be measured every 8 hrs using Electrical Cardiometry monitor, ICON
Cardiotronics, Inc., La Jolla, CA 92307; Osypka Medical GmbH, Berlin,Germany and will be
compared between both groups during the period of the studied drugs adminstration.
7. Total dose of vasopressor therapy.
8. Serum lactate level will be measured daily during the period of the studied drugs
administration.
9. Serum pocalcitonin level will be measured at time of starting the studied drugs
administration and at the end of it.
